Protagonist Therapeutics, Inc. (NASDAQ:PTGX) insider Richard S. Shames sold 1,512 shares of the stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $17.00, for a total value of $25,704.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Protagonist Therapeutics, Inc. (PTGX) traded down 0.91% during midday trading on Thursday, reaching $16.33. The company’s stock had a trading volume of 44,594 shares. The company’s market cap is $276.01 million. The stock has a 50-day moving average of $12.43 and a 200 day moving average of $12.09. Protagonist Therapeutics, Inc. has a 12 month low of $8.00 and a 12 month high of $26.36.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.70.

ILLEGAL ACTIVITY WARNING: This report was first posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/protagonist-therapeutics-inc-ptgx-insider-richard-s-shames-sells-1512-shares/1534753.html.

Several large investors have recently modified their holdings of the stock. Rhumbline Advisers acquired a new stake in shares of Protagonist Therapeutics during the second quarter worth approximately $114,000. Teachers Advisors LLC boosted its stake in Protagonist Therapeutics by 71.4% in the second quarter. Teachers Advisors LLC now owns 16,218 shares of the company’s stock valued at $183,000 after buying an additional 6,757 shares during the last quarter. Northern Capital Management LLC purchased a new stake in Protagonist Therapeutics during the second quarter valued at about $188,000. California State Teachers Retirement System boosted its stake in Protagonist Therapeutics by 8.5% in the second quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock valued at $188,000 after buying an additional 1,300 shares during the last quarter. Finally, TIAA CREF Investment Management LLC boosted its stake in Protagonist Therapeutics by 19.5% in the second quarter. TIAA CREF Investment Management LLC now owns 23,372 shares of the company’s stock valued at $264,000 after buying an additional 3,812 shares during the last quarter. Institutional investors and hedge funds own 48.19% of the company’s stock.

A number of brokerages have commented on PTGX. BMO Capital Markets raised their price objective on Protagonist Therapeutics from $34.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 31st. Zacks Investment Research upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 10th. BTIG Research began coverage on Protagonist Therapeutics in a research report on Friday, July 21st. They set a “buy” rating and a $36.00 price objective for the company. Finally, ValuEngine upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $26.00.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Receive News & Ratings for Protagonist Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.